| LncRNA FAM83H-AS1 inhibits ferroptosis of endometrial cancer by promoting DNMT1-mediated CDO1 promoter hypermethylation. | LncRNA FAM83H-AS1 inhibits ferroptosis of endometrial cancer by promoting DNMT1-mediated CDO1 promoter hypermethylation.
Wang R, Yu X, Ye H, Ao M, Xi M, Hou M., Free PMC Article | 10/8/2024 |
| [Molecular mechanism of CDO1 regulating common metabolic diseases]. | [Molecular mechanism of CDO1 regulating common metabolic diseases].
Liu Q, Shen WQ. | 09/9/2024 |
| TRIM47-CDO1 axis dictates hepatocellular carcinoma progression by modulating ferroptotic cell death through the ubiquitin-proteasome system. | TRIM47-CDO1 axis dictates hepatocellular carcinoma progression by modulating ferroptotic cell death through the ubiquitin‒proteasome system.
Zhang J, Yimamu M, Cheng Z, Ji J, Wu L, Feng J, Xu X, Wu J, Guo C. | 06/28/2024 |
| DNMT3L inhibits hepatocellular carcinoma progression through DNA methylation of CDO1: insights from big data to basic research. | DNMT3L inhibits hepatocellular carcinoma progression through DNA methylation of CDO1: insights from big data to basic research.
Yan X, Qi Y, Yao X, Zhou N, Ye X, Chen X., Free PMC Article | 02/7/2024 |
| Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells. | Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cells.
Yang J, Sun L, Liu XY, Huang C, Peng J, Zeng X, Zheng H, Cen W, Xu YX, Zhu W, Wu XY, Ling D, Zhang LL, Wei M, Liu Y, Wang D, Wang FH, Li YH, Li Q, Du Z., Free PMC Article | 09/26/2023 |
| Adipose tissue cysteine dioxygenase type 1 is associated with an anti-inflammatory profile, impacting on systemic metabolic traits. | Adipose tissue cysteine dioxygenase type 1 is associated with an anti-inflammatory profile, impacting on systemic metabolic traits.
Latorre J, Mayneris-Perxachs J, Oliveras-Cañellas N, Ortega F, Comas F, Fernández-Real JM, Moreno-Navarrete JM., Free PMC Article | 11/26/2022 |
| Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer. | Detection of Promoter DNA Methylation in Urine and Plasma Aids the Detection of Non-Small Cell Lung Cancer.
Liu B, Ricarte Filho J, Mallisetty A, Villani C, Kottorou A, Rodgers K, Chen C, Ito T, Holmes K, Gastala N, Valyi-Nagy K, David O, Gaba RC, Ascoli C, Pasquinelli M, Feldman LE, Massad MG, Wang TH, Jusue-Torres I, Benedetti E, Winn RA, Brock MV, Herman JG, Hulbert A., Free PMC Article | 10/30/2021 |
| Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN). | Promoter DNA Hypermethylation of the Cysteine Dioxygenase 1 (CDO1) Gene in Intraductal Papillary Mucinous Neoplasm (IPMN).
Fujiyama Y, Kumamoto Y, Nishizawa N, Nakamoto S, Harada H, Yokota K, Tanaka Y, Igarashi K, Oiki H, Okuwaki K, Iwai T, Kajita S, Takahashi H, Tajima H, Kaizu T, Sasaki J, Watanabe M, Yamashita K. | 05/8/2021 |
| Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer. | Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
Harada H, Soeno T, Yokoi K, Nishizawa N, Ushiku H, Hosoda K, Hiki N, Yamashita K. | 03/13/2021 |
| CDO1 is preferentially silenced by promoter methylation in human non-small cell lung cancers (NSCLC) harboring mutations in KEAP1, the negative regulator of NRF2. CDO1 silencing promotes proliferation of NSCLC by limiting the futile metabolism of cysteine to the wasteful and toxic byproducts cysteine sulfinic acid and sulfite (SO3(2-)), and depletion of cellular NADPH. | Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer.
Kang YP, Torrente L, Falzone A, Elkins CM, Liu M, Asara JM, Dibble CC, DeNicola GM., Free PMC Article | 02/29/2020 |
| Data show that nitric oxide ((*)NO), an oxygen surrogate, similarly binds to uncross-linked F2-Tyr157 cysteine dioxygenase (CDO) as in wild-type CDO. | Probing the Cys-Tyr Cofactor Biogenesis in Cysteine Dioxygenase by the Genetic Incorporation of Fluorotyrosine.
Li J, Koto T, Davis I, Liu A., Free PMC Article | 02/22/2020 |
| Anchorage independent growth was reduced in several gastric cancer cell lines due to forced expression of the CDO1 gene, suggesting that abnormal CDO1 gene expression may represent distant metastatic ability. | Cancer-specific promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene as an important prognostic biomarker of gastric cancer.
Harada H, Hosoda K, Moriya H, Mieno H, Ema A, Ushiku H, Washio M, Nishizawa N, Ishii S, Yokota K, Tanaka Y, Kaida T, Soeno T, Kosaka Y, Watanabe M, Yamashita K., Free PMC Article | 01/4/2020 |
| The CDO1 gene shows extremely cancer-specific hypermethylation, and it can be a prognostic marker in small bowel cancer. | Clinical significance of cancer specific methylation of the CDO1 gene in small bowel cancer.
Kojima K, Nakamura T, Ooizumi Y, Igarashi K, Tanaka T, Yokoi K, Ishii S, Nishizawa N, Katoh H, Kosaka Y, Sato T, Watanabe M, Yamashita K., Free PMC Article | 10/26/2019 |
| Promoter DNA methylation of CDO1 is extremely specific for pancreatic ductal adenocarcinoma (PDAC) tumors and accumulates with PDAC tumor progression. It could be a definitive diagnostic marker of PDAC in pancreatic juice or endoscopic ultrasound-fine needle aspiration cytology. | Diagnostic potential of hypermethylation of the cysteine dioxygenase 1 gene (CDO1) promoter DNA in pancreatic cancer.
Nishizawa N, Harada H, Kumamoto Y, Kaizu T, Katoh H, Tajima H, Ushiku H, Yokoi K, Igarashi K, Fujiyama Y, Okuwaki K, Iwai T, Watanabe M, Yamashita K., Free PMC Article | 10/5/2019 |
| High expression of CDO1 gene increased chemoresistance in Colon Cancer. | Epigenetic Status of CDO1 Gene May Reflect Chemosensitivity in Colon Cancer with Postoperative Adjuvant Chemotherapy.
Yokoi K, Harada H, Yokota K, Ishii S, Tanaka T, Nishizawa N, Shimazu M, Kojo K, Miura H, Yamanashi T, Sato T, Nakamura T, Watanabe M, Yamashita K. | 05/25/2019 |
| In the present study, we compared the 2 potential epigenetic prognostic markers of CDO1 hypermethylation and HOPX hypermethylation using the same breast cancer samples, and the final focus was given on CDO1 hypermethylation | Differential Prognostic Relevance of Promoter DNA Methylation of CDO1 and HOPX in Primary Breast Cancer.
Tanaka Y, Kosaka Y, Waraya M, Yokota K, Harada H, Kaida T, Kikuchi M, Minatani N, Nishimiya H, Katoh H, Sengoku N, Watanabe M, Yamashita K. | 05/25/2019 |
| CDO1 hypermethylation, preoperative serum CA19-9 and perineural invasion were independent prognostic factors in primary extrahepatic cholangiocarcinoma | Methylated promoter DNA of CDO1 gene and preoperative serum CA19-9 are prognostic biomarkers in primary extrahepatic cholangiocarcinoma.
Nakamoto S, Kumamoto Y, Igarashi K, Fujiyama Y, Nishizawa N, Ei S, Tajima H, Kaizu T, Watanabe M, Yamashita K., Free PMC Article | 04/6/2019 |
| High CDO1 methylation is associated with colorectal cancer progression. | Cysteine dioxygenase type 1 (CDO1) gene promoter methylation during the adenoma-carcinoma sequence in colorectal cancer.
Kojima K, Nakamura T, Ohbu M, Katoh H, Ooizumi Y, Igarashi K, Ishii S, Tanaka T, Yokoi K, Nishizawa N, Yokota K, Kosaka Y, Sato T, Watanabe M, Yamashita K., Free PMC Article | 08/4/2018 |
| Promoter NA methylation of CDO1 was demonstrated for the first time to be a cancer-associated methylation in primary gallbladder cancer(GBC), and it has the potential to be a prognostic biomarker of GBC for high-risk patients with stage II GBC. | Prognostic significance of promoter DNA hypermethylation of the cysteine dioxygenase 1 (CDO1) gene in primary gallbladder cancer and gallbladder disease.
Igarashi K, Yamashita K, Katoh H, Kojima K, Ooizumi Y, Nishizawa N, Nishiyama R, Kawamata H, Tajima H, Kaizu T, Kumamoto Y, Watanabe M., Free PMC Article | 12/9/2017 |
| CDO1 methylation could be a potent prognostic predictor in primary esophageal squamous cell carcinoma and have great potential as a prognostic factor to guide the treatment of patients who need adjuvant chemotherapy. | Promoter DNA methylation of CDO1 gene and its clinical significance in esophageal squamous cell carcinoma.
Ushiku H, Yamashita K, Katoh H, Ema A, Minatani N, Kikuchi M, Kojo K, Yokoi K, Tanaka T, Nishizawa N, Ishii S, Hosoda K, Moriya H, Mieno H, Katada N, Kikuchi S, Watanabe M. | 10/21/2017 |
| High methylation of CDO1 gene is responsible of the development of the esophageal adenocarcinoma. | The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma.
Kojima K, Yamashita K, Ushiku H, Katoh H, Ishii S, Tanaka T, Yokoi K, Suzuki M, Ooizumi Y, Igarashi K, Hosoda K, Moriya H, Mieno H, Katada N, Tanabe S, Watanabe M. | 09/2/2017 |
| CDO1 promoter methylation is involved in gene regulation and is a potential prognostic biomarker for BCR-free survival in prostate cancer (PC) patients following radical prostatectomy. Further studies are needed to validate CDO1 methylation assays and to evaluate the clinical utility of CDO1 methylation for the management of PCa | CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.
Meller S, Zipfel L, Gevensleben H, Dietrich J, Ellinger J, Majores M, Stein J, Sailer V, Jung M, Kristiansen G, Dietrich D., Free PMC Article | 05/27/2017 |
| methylation of the CDO1 gene promoter could be strong prognostic indicator in primary BC without preoperative treatment. | Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
Minatani N, Waraya M, Yamashita K, Kikuchi M, Ushiku H, Kojo K, Ema A, Nishimiya H, Kosaka Y, Katoh H, Sengoku N, Tanino H, Sidransky D, Watanabe M., Free PMC Article | 07/16/2016 |
| CDO1 promoter methylation may not substitute common prognostic makers to predict ccRCC survival, but offers additional, relevant prognostic information, indicating that it might be a novel molecular marker to determine ccRCC prognosis | Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome.
Deckers IA, Schouten LJ, Van Neste L, van Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman JG, van den Brandt PA, van Engeland M., Free PMC Article | 05/21/2016 |
| Decreased expression of CDO1 is associated with esophageal squamous cell carcinoma. | Epigenetic regulation of the novel tumor suppressor cysteine dioxygenase 1 in esophageal squamous cell carcinoma.
Kwon J, Park M, Kim JH, Lee HW, Kang MC, Park JH. | 02/6/2016 |